Sarah Aiosa – SVP & President Latin America, MSD
Sarah Aiosa, SVP and President of MSD (known as Merck & Co. in the U.S. and Canada) for Latin America, highlights nearly four years of strong growth built on a…
Address: Edificio Scotiabank Inverlat,Piso 12 / Blvd M. Avila Camacho ,1 1009 México D.F.,Mexico
Tel: 52 55 5279 2900
Web: http://www.bakermckenzie.com/Mexico/
Operating in Mexico for nearly 50 years, we have gained a deep understanding of local law and extensive experience assisting domestic and multinational companies. With five offices and a team of more than 240 seasoned professionals that includes lawyers, accountants and economists, we can bring the right talent to any kind of transaction within or outside Mexico. We are regularly involved in major M&A matters, privatization of government-owned companies, and complex financial transactions involving multiple jurisdictions.
We understand the importance of sharing our knowledge and resources, so we encourage and support our professionals in engaging in pro bono and community service activities. We give legal assistance to various charitable institutions, business and health organizations, carry out fund-raising activities to help nonprofit organizations, and participate in activities aimed at promoting good business practice and improving legal knowledge.
We are regularly involved in major M&A matters, privatization of government-owned companies, and complex financial transactions involving multiple jurisdictions.
Sarah Aiosa, SVP and President of MSD (known as Merck & Co. in the U.S. and Canada) for Latin America, highlights nearly four years of strong growth built on a…
Pharmaceutical innovators are sounding the alarm on Mexico’s healthcare reforms, despite the government’s bold claims. At industry group AMIIF’s 75th anniversary, Health Secretary David Kershenobich hailed the Sheinbaum administration’s investments…
In her latest strategy to tackle Mexico’s persistent medicine shortages – a struggle inherited from predecessor López Obrador – President Claudia Sheinbaum has issued a decree that seeks to attract…
Mexico has a long history of public healthcare reforms that have fluctuated along with the changing tides of the country’s government. The latest is an ambitious plan for the Institute…
Rare diseases, by definition, only affect small patient populations. However, when the more than 7,000 known rare conditions are taken together, their impact is enormous. Rare disease patients, for example,…
Whenever the international investor community contemplates doing business in Mexico’s life science sector, the primary appeal usually derives from the sheer size of the marketplace and its underlying growth potential…
Mexico has firmly established itself as a regional powerhouse in medical device manufacturing. The country is home to the second-largest medtech market in Latin America, employs around 160,000 people in…
Valued at USD 7.28 billion, the Mexican pharma market stands out within Latin America, ranking second only to Brazil, and registering a solid compound annual growth rate of six percent…
In recent decades, Mexico has gained notoriety as one of the countries most heavily afflicted by the global epidemic of obesity. Ranking second only to the United States in terms…
Mexico has long been considered a relatively appealing destination for clinical trials and, in recent years, has participated in more than one percent of global drug development research, generating an…
This interview explores Esmeralda Ortiz’s transformative leadership at Grupo Loeffler Russek (GLR), where she has worked to professionalize operations, strengthen the product portfolio, and position the company for sustainable growth.…
Karla Alcazar, Head of LATAM at Eli Lilly, discusses the company’s plans to tackle pressing regional health challenges such as obesity, diabetes, and cancer, while also highlighting the region’s critical…
See our Cookie Privacy Policy Here
